CAPRICOR THERAPEUTICS ($CAPR) posted quarterly earnings results on Wednesday, March 19th. The company reported earnings of -$0.16 per share, beating estimates of -$0.27 by $0.11. The company also reported revenue of $11,130,000, beating estimates of $5,795,303 by $5,334,697.
You can see Quiver Quantitative's $CAPR stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
CAPRICOR THERAPEUTICS Insider Trading Activity
CAPRICOR THERAPEUTICS insiders have traded $CAPR stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CAPR stock by insiders over the last 6 months:
- SHINYAKU CO LTD NIPPON purchased 2,798,507 shares for an estimated $14,999,997
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
CAPRICOR THERAPEUTICS Hedge Fund Activity
We have seen 79 institutional investors add shares of CAPRICOR THERAPEUTICS stock to their portfolio, and 39 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FARALLON CAPITAL MANAGEMENT LLC added 2,250,400 shares (+inf%) to their portfolio in Q4 2024, for an estimated $31,055,520
- STATE STREET CORP added 1,696,055 shares (+331.1%) to their portfolio in Q4 2024, for an estimated $23,405,559
- BLACKROCK, INC. added 1,216,907 shares (+69.5%) to their portfolio in Q4 2024, for an estimated $16,793,316
- VANGUARD GROUP INC added 700,243 shares (+44.4%) to their portfolio in Q4 2024, for an estimated $9,663,353
- WOODLINE PARTNERS LP added 629,934 shares (+inf%) to their portfolio in Q4 2024, for an estimated $8,693,089
- MORGAN STANLEY added 500,238 shares (+380.4%) to their portfolio in Q4 2024, for an estimated $6,903,284
- IKARIAN CAPITAL, LLC removed 300,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $4,140,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CAPRICOR THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $CAPR in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 10/21/2024
- Oppenheimer issued a "Outperform" rating on 10/14/2024
- H.C. Wainwright issued a "Buy" rating on 10/11/2024
- Maxim Group issued a "Buy" rating on 09/25/2024
- Cantor Fitzgerald issued a "Overweight" rating on 09/24/2024
To track analyst ratings and price targets for CAPRICOR THERAPEUTICS, check out Quiver Quantitative's $CAPR forecast page.
CAPRICOR THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $CAPR recently. We have seen 4 analysts offer price targets for $CAPR in the last 6 months, with a median target of $15.0.
Here are some recent targets:
- Edward Tenthoff from Piper Sandler set a target price of $17.5 on 10/21/2024
- Leland Gershall from Oppenheimer set a target price of $21.5 on 10/14/2024
- Jason McCarthy from Maxim Group set a target price of $12.5 on 09/25/2024
- Joseph Pantginis from H.C. Wainwright set a target price of $10.0 on 09/25/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
